# Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

> **NCT03258008** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites
- Malignant Neoplasms of Lip Oral Cavity and Pharynx
- Oropharyngeal Cancer

## Interventions

- **DRUG:** Utomilumab
- **BIOLOGICAL:** ISA101b

## Key facts

- **NCT ID:** NCT03258008
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-04
- **Primary completion:** 2021-11-05
- **Final completion:** 2021-11-05
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Closed the trial for infeasibility due to slow accrual
- **Last updated:** 2022-12-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03258008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03258008, "Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03258008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*